|
|
| March 15, 2010: Findings from the INternational VErapamil SR – Trandolapril STudy (INVEST) |
At ACC 2010, Rhonda M. Cooper-DeHoff, Pharm D, presents: Rethinking Lower Blood Pressure
Goals for Diabetic Patients with Coronary Artery Disease – Findings from the INternational
VErapamil SR – Trandolapril STudy (INVEST) .
- INVEST conduct and analysis was funded by Abbott Laboratories through 12/2008
- Cooper-DeHoff: research grant NHLBI (K23HL086558)
- Handberg: unrestricted educational grants AstraZeneca, AtCor Medical, Daiichi Sankyo,
Eli Lilly, Pfizer, Sanofi-Aventis, and Schering-Plough
- Bakris: research grants Juvenile Diabetes Research Foundation, Glaxo Smith Kline, Forest
Laboratories and CVRx; consultant Glaxo Smith Kline, Merck, Novartis,
Boehringer-Ingelheim, Takeda, Abbott Laboratories, Walgreen’s, Bristol Meyer
Squibb/Sanofi, Gilead, Forest Labs and CVRx.
- Pepine: research grants NHLBI, Baxter, Pfizer, GlaxoSmithKline, and Bioheart, Inc;
consultant Abbott Laboratories, Forest Labs, Novartis/Cleveland Clinic, NicOx, Angioblast,
Sanofi-Aventis, NIH, Medtelligence, and SLACK Inc; unrestricted educational grants
AstraZeneca, AtCor Medical, Daiichi Sankyo, Eli Lilly, Pfizer, Sanofi-Aventis, and
Schering-Plough.
- Gong, Bavry and Denardo: None
[ Download video ] |
|
No comments have been submitted
|